Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MARKET COMMENT: Retreat In World Oil Price Flattens London Equities

Wed, 04th Feb 2015 17:42

LONDON (Alliance News) - London stock prices ended flat Wednesday, weighed down by energy-related shares, after a slide in the price of oil offset a positive UK economic reading and the decision by China's central bank to cut its reserve ratio for banks.

The FTSE 100 ended down 0.2% at 6,860.02, the FTSE 250 finished flat at 16,571.64, while the AIM All-Share closed up 0.1% at 694.03.

At the UK equities close, Brent oil was priced at USD55.92 a barrel, reversing an earlier gain to USD58.01, though still well clear of the USD50 mark. The US Energy Information Administration said Wednesday that US crude oil stocks rose by 6.3 million barrels to 413.1 million barrels in the week ended January 30, up 1.6% on the week and 15% year on year.

"As declines set in, Brent crude had managed to remain above USD56 per barrel after investors were unwilling to push the commodity’s levels any higher," said Spreadex analyst Connor Campbell. "However, Brent shot down to USD55 per barrel as the latest high US crude oil figure saw an increase of 6.3 million barrels, following 8.9 and 10.1 million in the last two weeks."

In the FTSE 100, Tullow Oil ended down 5.2%, BP down 1.6%, Royal Dutch Shell 'B' down 1.8% and 'A' down 1.1%, and BG Group down 1.4%, all among the index's worst performers.

In the FTSE 250, Afren fell 6.3%, Premier Oil 5.8%, Hunting 4.7%, John Wood Group 3.7%, Petrofac 2.2%, and Ophir Energy 2.1%.

The UK service sector began the year strongly, according to the Markit Services Purchasing Managers' Index. The index for January came in at 57.2, ahead of the 56.3 reading expected by economists and the 55.8 level in December.

The pound rose following the PMI data and was quoted at the UK equities close at USD1.5206.

Meanwhile, the eurozone private sector was reported to have expanded in January at the fastest pace since July last year as output expanded in Germany, Italy and Spain. But the downturn in the French economy extended into its ninth month. The final eurozone composite output index rose to 52.6 in January from 51.4 in December. It also improved upon the flash reading of 52.2.

European stocks closed mixed, with the CAC 40 in Paris down 0.4%, and the DAX 30 in Frankfurt up 0.2%.

The focus in Europe remained on Greece as Finance Minister Yanis Varoufakis continued his tour of European capitals to drum up support for changes to the country's debt programme.

"Germany said it is completely unwilling to tolerate a debt haircut, and is seeking a comment from Greece stating it will drop its pre-election promises. Greek Finance Minister Varoufakis is having a tougher time winning allies, not a great sign ahead of his meeting with staunch debt-cut opposition Wolfgang Schauble tomorrow," Spreadex's Campbell said.

Varoufakis said he would meet German Finance Minister Wolfgang Schaeuble on Thursday - correcting impressions that his tour of capitals was going to skip Berlin in an apparent snub to Europe's paymaster.

In the US, data showed that private sector jobs growth in the US fell short of expectations in January. Report released by payroll processor ADP showed that private sector employment increased by 213,000 jobs in January following an upwardly revised increase of 253,000 jobs in December.

The US non-manufacturing ISM purchase managers' index remained flat in January at 56.7, slightly above 56.3 economists forecasts, and also above the previous reading of 56.2 in December.

"The ISM report suggested that the US economy is heading in the right direction, but that there are concerns over the country’s job figures. Its unemployment claims tomorrow will give a better indication of this trend ahead of the all-important non-farm data on Friday," Campbell said.

The US reports initial and continuing jobless claim at 1330 GMT on Thursday, followed by non-farm payrolls at the same time on Friday.

The US service sector growth remained solid in January, according to a report from Markit on Wednesday. The services PMI index for January came in at 54.2, slightly above the flash reading of 54.0. The composite index also improved upon the flash reading at 54.4 versus 54.2.

At the London equities close, Wall Street was trading flat to higher. The DJIA was up 0.4%, while the S&P 500 was flat and the Nasdaq Composite was up 0.1%.

In China, the People's Bank of China reduced the reserve requirement ratio of banks by 0.5 percentage point to 19.5% with effect from February 5. This gave London's mining stocks a small boost during the morning, with Fresnillo closing up 0.9%.

ARM Holdings closed up 3.1% as the best performer in FTSE 100. The chip designer announced Tuesday a new suite of intellectual properties that are expected to be launched on mobile devices in 2016, including its ARM Cortex-A72 processor. The group said that in target configurations, the new processor well deliver CPU performance that is 50 times that of leading smartphones from five years ago.

In addition, Sony, one of ARM's main customers, raised its guidance for its full year, forecasting a smaller than initially expected loss. The Japanese company's provisional results showed stronger than expected revenue growth.

Also in the FTSE 100, Sky ended up 1.3%. The broadcaster posted a big increase in pretax profit for the first half of its financial year, boosted by a rise in revenue and exceptional gains from the sale of its stakes in ITV, which was the best FTSE 100 performer, up 2.9%, and the National Geographic Channel.

In its first results incorporating its acquisitions of Sky Italia and a majority stake in Sky Deutschland, Sky posted a pretax profit of GBP1.21 billion for the half year to end-December, compared with GBP507 million a year before, as revenue rose to GBP4.30 billion from GBP3.67 billion.

GlaxoSmithKline also ended among the best blue-chip performers, up 1.6%. The company reported a drop in pretax profit for 2014, hit by lower revenue for asthma and chronic obstructive pulmonary disease treatment Advair, and said that it was continuing to evaluate the possibility of an initial public offering for a minority stake in its HIV joint venture ViiV Healthcare.

The company sweetened the news for shareholders by raising its total dividend to 80 pence from 78 pence a year before, pledging to maintain this dividend level for 2015, and reiterating plans to return GBP4 billion of net proceeds from its transaction with Novartis to shareholders in 2015.

Also connected to the Novartis deal, Glaxo said separately near the close of trading that it is selling its 7.9% stake in Danish biotechnology company Genmab A/S via a share placing. GlaxoSmithKline currently holds 4.47 million shares in Copenhagen-listed Genmab. The stock closed Wednesday at DKK471.00, making Glaxo's stake worth DKK2.11 billion or GBP212.4 million.

Hargreaves Lansdown, down 8.5%, finished as the worst performer in the FTSE 100. The investment management product provider reported a drop in first-half pretax profit despite a rise in assets under administration over the course of the six months, in what was described as a "muted" time for stocks and retail investors.

In the economic calendar Thursday, German factory orders are due at 0700 GMT, followed by Bank Of England interest rate decision at 1200 GMT.

In the corporate calendar, Vodafone Group will provide an interim management statement, as will as Compass Group and Enterprise Inns. AstraZeneca and Smith & Nephew will release full-year results, and easyJet will publish its January Traffic Statistics.

By Daniel Ruiz; danielruiz@alliancenews.com

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.